ZHANG Ya-chen, LU Bao-jing, ZHAO Mei-hua, RONG Ye-zhi, CHEN Rui-ming
Department of Internal Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University, Shanghai (200092), China.
Chin J Integr Med. 2008 Dec;14(4):281-5. doi: 10.1007/s11655-008-0281-3. Epub 2008 Dec 12.
To study the effect of Shengmai injection (, SMI) on vascular endothelial and heart functions in coronary heart disease patients complicated with diabetes mellitus (CHD-DM).
One hundred and twenty patients with CHD-DM, their diagnosis confirmed by coronary arteriography, were equally randomized into a control group treated with conventional treatment and a treated group treated with conventional treatment plus SMI. The changes in blood levels of nitric oxide (NO), endothelin-1 (ET-1) and angiotensin II (Ang II), as well as endothelium-dependent vascular dilating function and heart function in the patients were observed before treatment and after the 3-week treatment.
After being treated with SMI for 3 weeks, in the treated group, blood level of NO was raised significantly from 69.8 + or - 33.1 micro mol/L to 120.1 + or - 50.8 micro mol/L, and ET-1 was lowered from 70.1 + or - 32.1 ng/L to 46.2 + or - 21.3 ng/L, respectively (P<0.01); that of Ang II was lowered from 81.3 + or - 24.3 ng/L to 50.2 + or - 27.3 ng/L (P<0.01); brachial arterial post-congestion blood flow increasing rate was raised from 389.4 + or - 26.3% to 459.3 + or - 27.8% (P<0.01); and the improvement in heart function as seen through the ejection fraction (EF) was increased from 44 + or - 5% to 68 + or - 6% (P<0.01), all the changes being more significant than those in the control group (all P<0.01).
SMI can improve not only the endothelial function in CHD-DM patients, but also heart contraction significantly.
研究生脉注射液（SMI）对冠心病合并糖尿病（CHD-DM）患者血管内皮功能和心脏功能的影响。
120例经冠状动脉造影确诊的CHD-DM患者，随机分为对照组和治疗组，每组60例。对照组采用常规治疗，治疗组在常规治疗基础上加用SMI。观察两组患者治疗前及治疗3周后血浆一氧化氮（NO）、内皮素-1（ET-1）、血管紧张素Ⅱ（AngⅡ）水平变化，以及血管内皮依赖性舒张功能和心脏功能变化。
治疗组治疗3周后，血浆NO水平由（69.8±33.1）μmol/L显著升高至（120.1±50.8）μmol/L，ET-1水平由（70.1±32.1）ng/L降至（46.2±21.3）ng/L（P<0.01）；AngⅡ水平由（81.3±24.3）ng/L降至（50.2±27.3）ng/L（P<0.01）；肱动脉充血后血流增加率由（389.4±26.3）%升至（459.3±27.8）%（P<0.01）；左室射血分数（EF）由（44±5）%升至（68±6）%（P<0.01）。治疗组上述各项指标变化均较对照组显著（均P<0.01）。
SMI不仅能改善CHD-DM患者的血管内皮功能，而且能显著改善心脏收缩功能。
